Literature DB >> 7327068

Therapy of experimental tuberculosis in guinea pigs with mycobacterial phages DS-6A, GR-21 T, My-327.

L Sula, J Sulová, M Stolcpartová.   

Abstract

Guinea pigs, weighing 250-350 g, were infected with approximately 5,000 of live germs M- tuberculosis H 37 Rv grown 10 days in deep culture of liquid semisynthetic medium according to Sula. The infection was performed subcutaneously in inquinal region. For the therapy following phages were used: DS-6A, GR-21/T, My-327 injected twice a week subcutaneously in the dose of 10(6)/1 ml of live particles for 10 weeks. The therapeutic effect was expressed by spleen and hilus index. Out of the phages used, phage DS-6A had the highest therapeutic effect with mean spleen index of 0.19, corresponding approximately to the spleen index reached with the most effective tuberculostaticum INH. The exact explanation of the phage therapeutic effect in given experimental conditions, when the phages are not applied locally in order to gain the direct contact with infectious antigens, is not known. It is suggested that there presumably exists an interaction between the released phage nucleic acid and the nucleic acid synthesis needed for the growth of mycobacteria in vivo.

Entities:  

Mesh:

Year:  1981        PMID: 7327068

Source DB:  PubMed          Journal:  Czech Med        ISSN: 0139-9179


  11 in total

1.  Impact of relative humidity and collection media on mycobacteriophage D29 aerosol.

Authors:  Keyang Liu; Zhanbo Wen; Na Li; Wenhui Yang; Jie Wang; Lingfei Hu; Xiaokai Dong; Jianchun Lu; Jinsong Li
Journal:  Appl Environ Microbiol       Date:  2011-12-22       Impact factor: 4.792

2.  Molecular Genetics of Mycobacteriophages.

Authors:  Graham F Hatfull
Journal:  Microbiol Spectr       Date:  2014-03-07

3.  Fluorescent Reporter DS6A Mycobacteriophages Reveal Unique Variations in Infectibility and Phage Production in Mycobacteria.

Authors:  Oren Mayer; Paras Jain; Torin R Weisbrod; Daniel Biro; Libby Ho; Deborah Jacobs-Sera; Graham F Hatfull; William R Jacobs
Journal:  J Bacteriol       Date:  2016-11-04       Impact factor: 3.490

Review 4.  Actinobacteriophages: Genomics, Dynamics, and Applications.

Authors:  Graham F Hatfull
Journal:  Annu Rev Virol       Date:  2020-09-29       Impact factor: 10.431

5.  Phage therapy as a renewed therapeutic approach to mycobacterial infections: a comprehensive review.

Authors:  Taher Azimi; Mehrdad Mosadegh; Mohammad Javad Nasiri; Sahar Sabour; Samira Karimaei; Ahmad Nasser
Journal:  Infect Drug Resist       Date:  2019-09-17       Impact factor: 4.003

Review 6.  Bacteriophages as Alternatives to Antibiotics in Clinical Care.

Authors:  Danitza Romero-Calle; Raquel Guimarães Benevides; Aristóteles Góes-Neto; Craig Billington
Journal:  Antibiotics (Basel)       Date:  2019-09-04

Review 7.  Mycobacteriophages as Potential Therapeutic Agents against Drug-Resistant Tuberculosis.

Authors:  Anna Allué-Guardia; Rajagopalan Saranathan; John Chan; Jordi B Torrelles
Journal:  Int J Mol Sci       Date:  2021-01-13       Impact factor: 5.923

Review 8.  Phage Therapy for Mycobacterium Abscessus and Strategies to Improve Outcomes.

Authors:  Abdolrazagh Hashemi Shahraki; Mehdi Mirsaeidi
Journal:  Microorganisms       Date:  2021-03-14

Review 9.  A Phage Therapy Guide for Clinicians and Basic Scientists: Background and Highlighting Applications for Developing Countries.

Authors:  Ali Khalid; Ruby C Y Lin; Jonathan R Iredell
Journal:  Front Microbiol       Date:  2021-02-11       Impact factor: 5.640

10.  Phylogenetic relationships and codon usage bias amongst cluster K mycobacteriophages.

Authors:  Adele Crane; Cyril J Versoza; Tiana Hua; Rohan Kapoor; Lillian Lloyd; Rithik Mehta; Jueliet Menolascino; Abraham Morais; Saige Munig; Zeel Patel; Daniel Sackett; Brandon Schmit; Makena Sy; Susanne P Pfeifer
Journal:  G3 (Bethesda)       Date:  2021-10-19       Impact factor: 3.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.